340 related articles for article (PubMed ID: 24560166)
1. Blood transfusion practices in dialysis patients in a dynamic regulatory environment.
Hirth RA; Turenne MN; Wilk AS; Wheeler JR; Sleeman KK; Zhang W; Paul MA; Nahra TA; Messana JM
Am J Kidney Dis; 2014 Oct; 64(4):616-21. PubMed ID: 24560166
[TBL] [Abstract][Full Text] [Related]
2. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
[TBL] [Abstract][Full Text] [Related]
3. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
4. Does One Size Fit All With the Effects of Payment Reform? Dialysis Facility Payer Mix and Anemia Management Under the Expanded Medicare Prospective Payment System.
Mukhopadhyay P; Pearson J; Cogan C; Gaber C; Gillespie BW; Turenne M
Med Care; 2019 Aug; 57(8):584-591. PubMed ID: 31295188
[TBL] [Abstract][Full Text] [Related]
5. Development of a standardized transfusion ratio as a metric for evaluating dialysis facility anemia management practices.
Liu J; Li S; Gilbertson DT; Monda KL; Bradbury BD; Collins AJ
Am J Kidney Dis; 2014 Oct; 64(4):608-15. PubMed ID: 24820317
[TBL] [Abstract][Full Text] [Related]
6. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
[TBL] [Abstract][Full Text] [Related]
7. The initial impact of Medicare's new prospective payment system for kidney dialysis.
Hirth RA; Turenne MN; Wheeler JR; Nahra TA; Sleeman KK; Zhang W; Messana JA
Am J Kidney Dis; 2013 Oct; 62(4):662-9. PubMed ID: 23769138
[TBL] [Abstract][Full Text] [Related]
8. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis.
Spoendlin J; Schneeweiss S; Tsacogianis T; Paik JM; Fischer MA; Kim SC; Desai RJ
Am J Kidney Dis; 2018 Aug; 72(2):178-187. PubMed ID: 29891194
[TBL] [Abstract][Full Text] [Related]
9. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
10. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis.
Hornberger J; Hirth RA
Am J Kidney Dis; 2012 Aug; 60(2):280-7. PubMed ID: 22560829
[TBL] [Abstract][Full Text] [Related]
11. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
[TBL] [Abstract][Full Text] [Related]
12. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
13. Medicare program; end-stage renal disease prospective payment system. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
[TBL] [Abstract][Full Text] [Related]
14. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
16. Payment Reform and Health Disparities: Changes in Dialysis Modality under the New Medicare Dialysis Payment System.
Turenne M; Baker R; Pearson J; Cogan C; Mukhopadhyay P; Cope E
Health Serv Res; 2018 Jun; 53(3):1430-1457. PubMed ID: 28560726
[TBL] [Abstract][Full Text] [Related]
17. Medicare programs: changes to the end-stage renal disease prospective payment system transition budget-neutrality adjustment. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2011 Apr; 76(66):18930-4. PubMed ID: 21491804
[TBL] [Abstract][Full Text] [Related]
18. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
Park H; Rascati KL; Keith MS
J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
[TBL] [Abstract][Full Text] [Related]
19. Variation in patient routine costliness in U.S. psychiatric facilities.
Cromwell J; Drozd EM; Gage B; Maier J; Richter E; Goldman HH
J Ment Health Policy Econ; 2005 Mar; 8(1):15-28. PubMed ID: 15870482
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell transfusion use in patients with chronic kidney disease.
Gill KS; Muntner P; Lafayette RA; Petersen J; Fink JC; Gilbertson DT; Bradbury BD
Nephrol Dial Transplant; 2013 Jun; 28(6):1504-15. PubMed ID: 23389999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
